Literature DB >> 28573462

Mast cell activator compound 48/40 is not an effective adjuvant for UV-attenuated Toxoplasma gondii vaccine.

Xi Li1,2, Shengjie Chen1,2, Shiguang Huang3, Fangli Lu4,5.   

Abstract

Toxoplasma gondii (T. gondii, Tg) is a globally distributed parasitic protozoan causing different forms of toxoplasmosis in humans. Mast cells (MCs) play a role during T. gondii infection. Several studies suggest that MC activator compound 48/80 (C48/80) may be an effective vaccine adjuvant resulting in a potent and protective antigen-specific immune response against bacteria or virus infections. The present study was performed to determine whether C48/80 had adjuvant activity for ultraviolet (UV)-attenuated T. gondii vaccine to induce protective immune responses against T. gondii in mouse model. Kunming mice were divided into the following groups: naive mice, naive mice administrated with C48/80 intraperitoneal (i.p.) injection, mice infected by i.p. injection of 104 T. gondii RH strain alone (Tg group), mice infected with 104 RH tachyzoites plus C48/80 administration (Tg + C48/80), mice immunized with UV-Tg alone, and mice immunized with UV-Tg plus C48/80 administration (UV-Tg + C48/80). All the vaccinated mice were challenged with 104 tachyzoites of T. gondii RH strain at the same time as the primary infection. The survival rates, liver histopathologies, liver parasite burdens, and mRNA expression levels of Th1 and Th2 cytokines in the livers and spleens detected by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) were compared among the aforementioned groups after primary infection or challenge infection. The results showed that, compared to the Tg group or Tg + C48/80 group, the UV-Tg + Tg group and UV-Tg + C48/80 + Tg group had significantly prolonged survival time, lower liver histopathological scores, decreased liver parasite burdens, and increased levels of Th1 and Th2 cytokines in the livers and spleens. There was no significant difference of survival time between the UV-Tg + Tg group and the UV-Tg + C48/80 + Tg group; however, the UV-Tg + C48/80 + Tg group showed higher parasite burden, more severe liver histopathology, and decreased IL-4 level compared to the UV-Tg + Tg group. These results indicate that C48/80 had no adjuvant activity for the immunization induced by UV-attenuated T. gondii vaccine.

Entities:  

Keywords:  Adjuvant; Compound 48/80; Mice; UV-attenuated T. gondii

Mesh:

Substances:

Year:  2017        PMID: 28573462     DOI: 10.1007/s00436-017-5522-y

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  31 in total

1.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

Review 2.  Vaccines against Toxoplasma gondii: challenges and opportunities.

Authors:  Erik Jongert; Craig W Roberts; Nicola Gargano; Elisabeth Förster-Waldl; Elisabeth Förster-Wald; Eskild Petersen
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 3.  Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.

Authors:  E A Innes; A N Vermeulen
Journal:  Parasitology       Date:  2006       Impact factor: 3.234

4.  Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.

Authors:  Lingbin Zeng; Yusi Liu; Hong Wang; Pu Liao; Zhixin Song; Song Gao; Yingying Wu; Xuemei Zhang; Yibing Yin; Wenchun Xu
Journal:  Vaccine       Date:  2015-01-14       Impact factor: 3.641

5.  Relation between mast cells concentration and serotonin expression in chagasic megacolon development.

Authors:  M A R Freitas; N Segatto; N Tischler; E C de Oliveira; A Brehmer; A B M da Silveira
Journal:  Parasite Immunol       Date:  2017-03       Impact factor: 2.280

6.  Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.

Authors:  Mei Zheng; Fen Liu; Yiqing Shen; Shilei Wang; Wenting Xu; Fang Fang; Bing Sun; Zhenyuan Xie; Ze Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Upregulated expression of Tim-3 involved in the process of toxoplasmic encephalitis in mouse model.

Authors:  Bin Wu; Bo Huang; Ying Chen; Shaoyuan Li; Junping Yan; Huanqin Zheng; Shiguang Huang; Jilong Shen; Zhao-Rong Lun; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  Parasitol Res       Date:  2013-04-18       Impact factor: 2.289

8.  Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication.

Authors:  Jason P Gigley; Barbara A Fox; David J Bzik
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

9.  The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.

Authors:  Afton L McGowen; Laura P Hale; Christopher P Shelburne; Soman N Abraham; Herman F Staats
Journal:  Vaccine       Date:  2009-04-14       Impact factor: 3.641

10.  Mast cells modulate acute toxoplasmosis in murine models.

Authors:  Bo Huang; Shiguang Huang; Ying Chen; Huanqin Zheng; Jilong Shen; Zhao-Rong Lun; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more
  3 in total

1.  Oral inoculation of ultraviolet-irradiated Eimeria species oocysts protects chickens against coccidiosis.

Authors:  Saeed A El-Ashram; Shawky M Aboelhadid; Sahar M Gadelhaq; Walid M Arafa; Abdel-Razik H Abdel-Razik; Salama Abohamra; Khaled T Abdelaziz
Journal:  Parasitol Res       Date:  2019-10-12       Impact factor: 2.289

Review 2.  Mast Cell Functions Linking Innate Sensing to Adaptive Immunity.

Authors:  Konstantinos Katsoulis-Dimitriou; Johanna Kotrba; Martin Voss; Jan Dudeck; Anne Dudeck
Journal:  Cells       Date:  2020-11-25       Impact factor: 6.600

Review 3.  Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.

Authors:  Steven Willows; Marianna Kulka
Journal:  Cells       Date:  2020-12-18       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.